secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091219
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Pharma Q2 loss $10M; CRB-701 shows 44% ORR in mUC; cash runway through Q3 2027
--------------------------------------------------------------------------------

- Net loss of $10.0M ($0.90 per diluted share) for Q2 2024, compared to net loss of $8.8M ($2.05 per share) in Q2 2023.
- Cash and investments of $147M at June 30; raised $28.8M additional through Aug 1; cash runway extended through Q3 2027.
- CRB-701 Phase 1 data: 44% ORR and 78% DCR in metastatic urothelial cancer; 43% ORR and 86% DCR in cervical cancer at doses ≥1.2mg/kg.
- US/EU Phase 1 dose escalation for CRB-701 commenced April 2024; completion expected Q4 2024; data presentation Q1 2025.
- CRB-913 Phase 1 start expected Q1 2025; CRB-601 Phase 1 start expected Q4 2024; both pre-clinical data support advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024091219/0000950170-24-091219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024091219/crbp-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer